Academic Journals Database
Disseminating quality controlled scientific knowledge

Pharmacoeconomic analysis of carvedilol therapy in patients with arterial hypertension and metabolic risk factors (according to the CAMELLIA study)

Author(s): S.Y. Martsevich | N.P. Kutishenko | A.D. Deev | S.A. Shalnova | R.G. Oganov

Journal: Racionalʹnaâ Farmakoterapiâ v Kardiologii
ISSN 1819-6446

Volume: 6;
Issue: 4;
Start page: 485;
Date: 2010;
Original page

Keywords: аrterial hypertension | obesity | carvedilol | metoprolol | pharmacoeconomic analysis.

Aim. To perform cost-effectiveness analysis of 24 weeks antihypertensive therapy based on carvedilol or metoprolol in patients with arterial hypertension (HT) 1-2 degrees and overweight/obesity. To assess effects of carvedilol therapy on 10-year expected risk of cardiovascular complications (CVC).Material and methods. Patients with HT and overweight/obesity (n=320) were included into the study and randomly split in two groups. Patients of the first group (n=160) received carvedilol as a basic therapy and patients of the second group (n=160) — metoprolol. Both groups of the patients were comparable on key clinical characteristics.Results. In 24 weeks of treatment systolic and diastolic blood pressure (BP) decreased significantly in comparison with the baseline level (p0.05). Target BP levels were achieved in carvedilol and metoprolol groups in 96.2and 95.5% of patients respectively (p=0.85). Carvedilol had better effect on plasma metabolic indicators such as glucose (p
Why do you need a reservation system?      Affiliate Program